5 Best ARK Stocks to Buy Right Now

2. CRISPR Therapeutics AG (NASDAQ:CRSP)

ARK Investment Management’s Stake Value: $538,189,027

On May 4, CRISPR Therapeutics AG (NASDAQ:CRSP) reported its first quarter 2026 results and advanced its pipeline and commercial launch. The company reported a net loss of $122.9 million for Q1 2026, lower than $136.0 million a year earlier. R&D expenses dipped to $68.6 million from $72.5 million, and G&A costs to $17.2 million from $19.3 million, the company said. Most importantly, its cash position actually strengthened, going up to $2.44 billion as of March 31, 2026, from $1.98 billion at the year’s end of 2025.

The company reported that CRISPR Therapeutics AG (NASDAQ:CRSP)’s CASGEVY had $43 million in revenue, with more than 500 patients having treatment worldwide.

CEO Samarth Kulkarni said the quarter showed “continued execution,” pointing out expanded Zugo Cel programs and continuous momentum for CASGEVY. He added that the corporation believes 2026 “will be a defining year,” noting multiple upcoming milestones.

CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene editing firm that works on the development of Crispr/Cas9-based therapies.

1281292 - 11759070 - 1